Kura Oncology (KURA) to Release Quarterly Earnings on Wednesday

Kura Oncology (NASDAQ:KURA - Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $57.96 million for the quarter. Parties that wish to listen to the company's conference call can do so using this link.

Kura Oncology Stock Performance

Kura Oncology stock traded up $0.10 during trading on Friday, reaching $8.25. The company had a trading volume of 971,849 shares, compared to its average volume of 1,683,910. The firm has a market capitalization of $641.21 million, a price-to-earnings ratio of -3.49 and a beta of 0.78. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm's 50-day simple moving average is $8.30 and its 200 day simple moving average is $14.19. Kura Oncology has a 52 week low of $6.98 and a 52 week high of $24.17.

Insiders Place Their Bets

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Mollie Leoni sold 4,963 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,729 shares of company stock worth $92,307 in the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on KURA shares. BTIG Research cut Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. JMP Securities reaffirmed a "market outperform" rating and set a $28.00 price target on shares of Kura Oncology in a report on Thursday, February 6th. Bank of America reduced their price objective on shares of Kura Oncology from $36.00 to $29.00 and set a "buy" rating for the company in a research note on Friday, November 22nd. Scotiabank lowered their target price on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating on the stock in a research note on Wednesday, January 8th. Finally, TD Cowen reiterated a "buy" rating on shares of Kura Oncology in a research note on Thursday, November 21st. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $27.13.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.